Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster | 25 | 2013 | 43 | 2.760 |
Why?
|
| Antiviral Agents | 19 | 2016 | 211 | 2.700 |
Why?
|
| Acyclovir | 19 | 2015 | 38 | 1.710 |
Why?
|
| Herpes Genitalis | 7 | 2016 | 12 | 1.460 |
Why?
|
| Herpesvirus 2, Human | 5 | 2016 | 10 | 0.930 |
Why?
|
| Encephalitis, Herpes Simplex | 3 | 2015 | 6 | 0.900 |
Why?
|
| West Nile Fever | 2 | 2019 | 7 | 0.810 |
Why?
|
| Herpes Zoster Vaccine | 6 | 2013 | 6 | 0.730 |
Why?
|
| West Nile virus | 2 | 2019 | 8 | 0.720 |
Why?
|
| Valine | 5 | 2015 | 43 | 0.710 |
Why?
|
| Central Nervous System Viral Diseases | 1 | 2019 | 5 | 0.690 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 52 | 0.670 |
Why?
|
| Herpesvirus 1, Human | 3 | 2016 | 30 | 0.590 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 481 | 0.570 |
Why?
|
| Chickenpox | 4 | 2012 | 14 | 0.560 |
Why?
|
| Herpes Simplex | 4 | 2013 | 35 | 0.550 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2016 | 6 | 0.550 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 11 | 0.540 |
Why?
|
| Blood Culture | 1 | 2016 | 15 | 0.540 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2016 | 35 | 0.540 |
Why?
|
| Chickenpox Vaccine | 2 | 2012 | 5 | 0.480 |
Why?
|
| Bacteremia | 1 | 2016 | 155 | 0.470 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2013 | 4 | 0.460 |
Why?
|
| Kaposi Varicelliform Eruption | 1 | 2013 | 2 | 0.460 |
Why?
|
| Encephalomyelitis, Eastern Equine | 1 | 2013 | 1 | 0.460 |
Why?
|
| Culex | 1 | 2013 | 3 | 0.460 |
Why?
|
| Animal Technicians | 1 | 2013 | 3 | 0.460 |
Why?
|
| Occupational Diseases | 1 | 2013 | 68 | 0.440 |
Why?
|
| Insect Bites and Stings | 1 | 2013 | 47 | 0.430 |
Why?
|
| Antirheumatic Agents | 2 | 2009 | 59 | 0.410 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2012 | 92 | 0.390 |
Why?
|
| Humans | 56 | 2021 | 68618 | 0.370 |
Why?
|
| Adult | 25 | 2021 | 21403 | 0.370 |
Why?
|
| Herpesvirus 3, Human | 6 | 2013 | 12 | 0.360 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2009 | 626 | 0.340 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 511 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 1026 | 0.330 |
Why?
|
| Aged | 22 | 2019 | 14862 | 0.320 |
Why?
|
| Neuralgia, Postherpetic | 4 | 2009 | 6 | 0.320 |
Why?
|
| Simplexvirus | 2 | 2007 | 26 | 0.300 |
Why?
|
| Female | 31 | 2019 | 38074 | 0.300 |
Why?
|
| Geriatrics | 1 | 2008 | 69 | 0.290 |
Why?
|
| Middle Aged | 24 | 2019 | 21147 | 0.280 |
Why?
|
| HIV-1 | 3 | 2003 | 177 | 0.270 |
Why?
|
| Antibodies, Viral | 2 | 2019 | 110 | 0.270 |
Why?
|
| Prednisone | 4 | 1999 | 104 | 0.270 |
Why?
|
| Pain | 5 | 2009 | 472 | 0.260 |
Why?
|
| HIV Infections | 3 | 2003 | 791 | 0.250 |
Why?
|
| HIV Seropositivity | 4 | 2003 | 66 | 0.250 |
Why?
|
| Male | 31 | 2021 | 37321 | 0.250 |
Why?
|
| RNA, Viral | 3 | 2005 | 93 | 0.240 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 4848 | 0.230 |
Why?
|
| Genital Diseases, Female | 1 | 2003 | 23 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2019 | 7029 | 0.210 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2004 | 85 | 0.210 |
Why?
|
| Encephalitis, Viral | 1 | 2002 | 5 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2018 | 234 | 0.200 |
Why?
|
| Incidence | 6 | 2012 | 1603 | 0.190 |
Why?
|
| Arabinofuranosyluracil | 2 | 1998 | 3 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 1999 | 123 | 0.190 |
Why?
|
| Herpesvirus 8, Human | 1 | 2000 | 24 | 0.180 |
Why?
|
| Sarcoma, Kaposi | 1 | 2000 | 25 | 0.180 |
Why?
|
| Double-Blind Method | 10 | 2013 | 1738 | 0.180 |
Why?
|
| Antibodies, Neutralizing | 1 | 2019 | 46 | 0.170 |
Why?
|
| 2-Aminopurine | 4 | 2008 | 5 | 0.170 |
Why?
|
| Recurrence | 5 | 2016 | 948 | 0.160 |
Why?
|
| Immunoglobulins | 2 | 2012 | 97 | 0.160 |
Why?
|
| Deltaretrovirus Infections | 2 | 1989 | 3 | 0.160 |
Why?
|
| Histoplasmosis | 1 | 2018 | 5 | 0.160 |
Why?
|
| Ascites | 1 | 2018 | 38 | 0.150 |
Why?
|
| Crohn Disease | 1 | 2018 | 38 | 0.150 |
Why?
|
| Prodrugs | 2 | 1999 | 54 | 0.150 |
Why?
|
| Adolescent | 6 | 2016 | 8912 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 25 | 0.140 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2016 | 19 | 0.140 |
Why?
|
| Quality of Life | 6 | 2015 | 1515 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 2223 | 0.130 |
Why?
|
| Young Adult | 3 | 2016 | 5717 | 0.130 |
Why?
|
| Vidarabine | 2 | 1992 | 12 | 0.120 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2013 | 7 | 0.120 |
Why?
|
| Viral Envelope Proteins | 4 | 2004 | 43 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 148 | 0.120 |
Why?
|
| HIV | 2 | 2000 | 56 | 0.120 |
Why?
|
| Neuralgia | 2 | 2005 | 27 | 0.110 |
Why?
|
| Clinical Trials as Topic | 6 | 2009 | 848 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 87 | 0.110 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 137 | 0.110 |
Why?
|
| Risk Factors | 6 | 2021 | 5731 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 142 | 0.110 |
Why?
|
| Peptides | 4 | 1989 | 455 | 0.110 |
Why?
|
| Immunization, Passive | 1 | 2012 | 24 | 0.100 |
Why?
|
| Preconception Care | 1 | 2012 | 14 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2012 | 26 | 0.100 |
Why?
|
| Postnatal Care | 1 | 2012 | 16 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2015 | 342 | 0.100 |
Why?
|
| Time Factors | 3 | 2016 | 4655 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2012 | 87 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1991 | 13 | 0.100 |
Why?
|
| Prenatal Care | 1 | 2012 | 117 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 772 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 179 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 3259 | 0.090 |
Why?
|
| Epitopes | 2 | 1989 | 146 | 0.090 |
Why?
|
| Pneumonia, Viral | 2 | 2012 | 154 | 0.090 |
Why?
|
| Herpesviridae Infections | 1 | 1990 | 23 | 0.090 |
Why?
|
| HIV Antibodies | 2 | 1989 | 28 | 0.090 |
Why?
|
| Rheumatic Diseases | 1 | 2009 | 35 | 0.080 |
Why?
|
| HIV-2 | 1 | 1989 | 4 | 0.080 |
Why?
|
| Oxycodone | 1 | 2009 | 10 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2008 | 931 | 0.080 |
Why?
|
| Delayed-Action Preparations | 1 | 2009 | 120 | 0.080 |
Why?
|
| Antigens, Viral | 2 | 1989 | 35 | 0.080 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2009 | 60 | 0.080 |
Why?
|
| Amines | 1 | 2009 | 98 | 0.080 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1987 | 4 | 0.080 |
Why?
|
| Sweden | 1 | 2007 | 21 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 157 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2009 | 208 | 0.070 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2006 | 12 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2008 | 291 | 0.070 |
Why?
|
| Ribavirin | 1 | 2006 | 27 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2008 | 328 | 0.070 |
Why?
|
| Pregnancy | 1 | 2012 | 2334 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2012 | 2455 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 438 | 0.070 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 91 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2003 | 98 | 0.060 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2004 | 3 | 0.060 |
Why?
|
| Immunocompetence | 2 | 2007 | 19 | 0.060 |
Why?
|
| Viral Load | 2 | 2006 | 127 | 0.060 |
Why?
|
| Adalimumab | 2 | 2018 | 16 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 245 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2005 | 86 | 0.060 |
Why?
|
| Animals | 4 | 2013 | 20881 | 0.060 |
Why?
|
| Sialic Acids | 1 | 2003 | 27 | 0.060 |
Why?
|
| Drug Therapy, Combination | 6 | 2004 | 649 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1753 | 0.050 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2002 | 4 | 0.050 |
Why?
|
| Influenza, Human | 1 | 2003 | 79 | 0.050 |
Why?
|
| Arboviruses | 1 | 2002 | 1 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2021 | 7277 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2005 | 400 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 1989 | 1083 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2014 | 3705 | 0.050 |
Why?
|
| Neuritis | 2 | 1999 | 4 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 186 | 0.050 |
Why?
|
| Fever | 1 | 2000 | 96 | 0.040 |
Why?
|
| Immunocompromised Host | 2 | 2007 | 55 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 135 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 384 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 344 | 0.040 |
Why?
|
| Itraconazole | 1 | 2018 | 2 | 0.040 |
Why?
|
| Histoplasma | 1 | 2018 | 4 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 26 | 0.040 |
Why?
|
| Peritonitis | 1 | 2018 | 46 | 0.040 |
Why?
|
| Acute Disease | 4 | 2009 | 658 | 0.040 |
Why?
|
| Child | 3 | 2002 | 6405 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2018 | 108 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2018 | 97 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 1999 | 319 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1989 | 507 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2003 | 2358 | 0.040 |
Why?
|
| Infusions, Intravenous | 3 | 1992 | 334 | 0.030 |
Why?
|
| Analgesics | 2 | 2008 | 118 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2018 | 237 | 0.030 |
Why?
|
| Myelitis, Transverse | 1 | 1995 | 2 | 0.030 |
Why?
|
| Placebos | 2 | 2012 | 195 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2014 | 737 | 0.030 |
Why?
|
| United States | 2 | 2021 | 7367 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 978 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 567 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 1989 | 1140 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1996 | 222 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 1994 | 18 | 0.030 |
Why?
|
| North America | 1 | 2012 | 112 | 0.020 |
Why?
|
| Vaccination | 1 | 2013 | 189 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 196 | 0.020 |
Why?
|
| Research Design | 1 | 1996 | 729 | 0.020 |
Why?
|
| Ampicillin | 1 | 1991 | 17 | 0.020 |
Why?
|
| Pyelonephritis | 1 | 1991 | 17 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1991 | 22 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1991 | 411 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 1990 | 70 | 0.020 |
Why?
|
| Infliximab | 1 | 2009 | 16 | 0.020 |
Why?
|
| Retroviridae Proteins | 1 | 1989 | 5 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1864 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2009 | 20 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1990 | 69 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 2093 | 0.020 |
Why?
|
| Texas | 1 | 2009 | 92 | 0.020 |
Why?
|
| New York | 1 | 2009 | 223 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 151 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2324 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1989 | 381 | 0.020 |
Why?
|
| Anesthetics | 1 | 2008 | 30 | 0.020 |
Why?
|
| HIV Antigens | 1 | 1987 | 9 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1989 | 362 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 1987 | 53 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 37 | 0.020 |
Why?
|
| Glomerulonephritis | 1 | 1987 | 77 | 0.020 |
Why?
|
| Aerosols | 1 | 2006 | 42 | 0.020 |
Why?
|
| Administration, Topical | 2 | 1984 | 111 | 0.020 |
Why?
|
| Rabbits | 1 | 1987 | 509 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1989 | 1447 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1987 | 238 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2005 | 10 | 0.020 |
Why?
|
| Half-Life | 1 | 2005 | 96 | 0.020 |
Why?
|
| Hepatitis | 1 | 2005 | 25 | 0.020 |
Why?
|
| Virus Activation | 1 | 2005 | 15 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 378 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1989 | 597 | 0.020 |
Why?
|
| Foscarnet | 1 | 2004 | 3 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2005 | 75 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2004 | 27 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2005 | 90 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2005 | 238 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 63 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2000 | 1330 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1983 | 62 | 0.010 |
Why?
|
| Chemistry | 1 | 1983 | 45 | 0.010 |
Why?
|
| Zanamivir | 1 | 2003 | 2 | 0.010 |
Why?
|
| Rimantadine | 1 | 2003 | 3 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2009 | 498 | 0.010 |
Why?
|
| Fibrosis | 1 | 2005 | 371 | 0.010 |
Why?
|
| Pyrans | 1 | 2003 | 16 | 0.010 |
Why?
|
| Drug Resistance, Viral | 1 | 2003 | 14 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2005 | 206 | 0.010 |
Why?
|
| Guanidines | 1 | 2003 | 32 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2003 | 34 | 0.010 |
Why?
|
| Respiratory Therapy | 1 | 2003 | 24 | 0.010 |
Why?
|
| Kinetics | 1 | 1983 | 1047 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1745 | 0.010 |
Why?
|
| Indinavir | 1 | 2000 | 2 | 0.010 |
Why?
|
| Lamivudine | 1 | 2000 | 24 | 0.010 |
Why?
|
| Zidovudine | 1 | 2000 | 27 | 0.010 |
Why?
|
| HIV Protease Inhibitors | 1 | 2000 | 25 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1983 | 307 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 28 | 0.010 |
Why?
|
| Syndrome | 1 | 2000 | 255 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2800 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1118 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1851 | 0.010 |
Why?
|
| Kidney | 1 | 1983 | 945 | 0.010 |
Why?
|
| Disease Progression | 1 | 2000 | 1038 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1999 | 384 | 0.010 |
Why?
|
| Meningoencephalitis | 1 | 1992 | 6 | 0.010 |
Why?
|
| Skin Diseases, Infectious | 1 | 1992 | 16 | 0.010 |
Why?
|
| Gentamicins | 1 | 1991 | 68 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1992 | 504 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1989 | 16 | 0.010 |
Why?
|
| Skin Tests | 1 | 1989 | 30 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1989 | 27 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 1989 | 19 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1989 | 41 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1989 | 94 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1989 | 420 | 0.000 |
Why?
|
| Streptococcus | 1 | 1987 | 15 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 442 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1989 | 397 | 0.000 |
Why?
|